| Title | Cancer Drug Discovery and Development |
| Abbreviation | Cancer Drug Discov. Dev. |
| Publication Type | Book series |
| Subject Area, Categories, Scope | Cancer Research (Q4); Drug Discovery (Q4); Oncology (Q4) |
| h-index | 7 |
| Overall Rank/Ranking | 30119 |
| SCImago Journal Rank (SJR) | 0.103 |
| Impact Score | 0.59 |
| Publisher | Springer New York |
| Country | United States |
| ISSN | 21969906, 21969914 |
| Best Quartile | Q4 |
| Coverage History | 2014-2015, 2017-2020, 2022 |
Cancer Drug Discovery and Development is a book series covering the technologies/fields/categories related to Cancer Research (Q4); Drug Discovery (Q4); Oncology (Q4). It is published by Springer New York. The overall rank of Cancer Drug Discovery and Development is 30119. According to SCImago Journal Rank (SJR), this book series is ranked 0.103. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This book series has an h-index of 7. The best quartile for this book series is Q4.
The ISSN of Cancer Drug Discovery and Development book series is 21969906, 21969914. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Cancer Drug Discovery and Development is cited by a total of 49 articles during the last 3 years (Preceding 2020).
The Impact IF 2020 of Cancer Drug Discovery and Development is 0.59, which is computed in 2021 as per its definition. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
| Year | Impact IF |
|---|---|
| 2023/2024 | Coming Soon |
| 2020 | 0.59 |
| 2017 | 0.18 |
| 2015 | 0.22 |
| 2014 | 0.00 |
Cancer Drug Discovery and Development has an h-index of 7. It means 7 articles of this book series have more than 7 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of Cancer Drug Discovery and Development is 21969906, 21969914. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of Cancer Drug Discovery and Development is 30119. According to SCImago Journal Rank (SJR), this book series is ranked 0.103. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
| Year | SJR |
|---|---|
| 2023/2024 | Coming Soon |
| 2020 | 0.103 |
| 2017 | |
| 2015 | |
| 2014 |
| Year | Ranking |
|---|---|
| 2023/2024 | Coming Soon |
| 2020 | 30119 |
| 2017 | 32672 |
| 2015 | 32121 |
| 2014 | 31526 |
Cancer Drug Discovery and Development is published by Springer New York. It's publishing house is located in United States. Coverage history of this book series is as following: 2014-2015, 2017-2020, 2022. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of Cancer Drug Discovery and Development is Cancer Drug Discov. Dev.. This abbreviation ('Cancer Drug Discov. Dev.') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Cancer Research (Q4); Drug Discovery (Q4); Oncology (Q4), then please visit the official website of this book series.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
Cancer Drug Discovery and Development latest impact IF is 0.59. It's evaluated in the year 2020. The highest and the lowest impact IF or impact score of this book series are 0.59 (2020) and 0.00 (2014), respectively, in the last 4 years. Moreover, its average IS is 0.25 in the previous 4 years.
The Cancer Drug Discovery and Development has an SJR (SCImago Journal Rank) of 0.103, according to the latest data. It is computed in the year 2021. In the past 4 years, this book series has recorded a range of SJR, with the highest being 0.103 in 2020 and the lowest being in 2017. Furthermore, the average SJR of the Cancer Drug Discovery and Development over the previous 4-year period stands at 0.25.
The latest h-index of the Cancer Drug Discovery and Development is 7.
The Cancer Drug Discovery and Development is published by the Springer New York, with its country of publication being the United States.
The Cancer Drug Discovery and Development is currently ranked 30119 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 4 years, this book series has experienced varying rankings, reaching its highest position of 30119 in 2020 and its lowest position of 32672 in 2017.
The standard ISO4 abbreviation for the Cancer Drug Discovery and Development is Cancer Drug Discov. Dev..
Cancer Drug Discovery and Development is classified as a book series that the Springer New York publishes.
The Cancer Drug Discovery and Development encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this book series.
The Cancer Drug Discovery and Development is assigned the following International Standard Serial Numbers (ISSN): 21969906, 21969914.
The best quartile for the Cancer Drug Discovery and Development is Q4 (2020).
The Cancer Drug Discovery and Development coverage history can be summarized as follows: 2014-2015, 2017-2020, 2022.
| Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
|---|---|---|---|---|---|
| Zeitschrift fur Germanistische Linguistik | journal | 22945 | De Gruyter Mouton | 15 | 0.19 |
| Entrepreneurship Theory and Practice | journal | 338 | Wiley-Blackwell | 185 | 12.75 |
| Discourse | journal | 6621 | Routledge | 59 | 2.11 |
| Transnational Corporations | journal | 6120 | UNCTAD United Nations Conference on Trade and Development | 27 | 1.92 |
| Educational Measurement: Issues and Practice | journal | 4494 | Wiley-Blackwell Publishing Ltd | 59 | 1.53 |
| Proteomics - Clinical Applications | journal | 9140 | Wiley-VCH Verlag | 59 | 2.02 |
| Engenharia Agricola | journal | 15839 | Sociedade Brasileira de Engenharia Agricola | 30 | 1.12 |
| Rudarsko Geolosko Naftni Zbornik | journal | 14294 | University of Zagreb, Faculty of Mining, Geology and Petroleum Engineering | 17 | 1.48 |
| Brazilian Symposium of Computer Graphic and Image Processing | conference and proceedings | 16004 | 32 | 0.00 | |
| Cuadernos de historia (Santiago, Chile) | journal | 20081 | Universidad de Chile | 4 | 0.25 |
| Year | Impact Score (IS) |
|---|---|
| 2021/2022 | Coming Soon |
| 2020 | 0.59 |
| 2017 | 0.18 |
| 2015 | 0.22 |
| 2014 | 0.00 |
